Abstract
The final goal of CKD-MBD (chronic kidney disease, mineral and bone disorder) is to reduce the risk of death in uremic patients. To achieve this objective, it is of importance to manage laboratory abnormalities, bone abnormalities, and vascular calcification appropriately. Many observation studies suggested that the good control of serum phosphate, calcium, and PTH concentration would lead to the lower risk of death. Fracture and vascular calcification would increase the risk for mortality. In addition, some randomized clinical trials have shown that the use of CKD-MBD related drugs, e.g. vitamin D, phosphate binder, might lead to reductions in the risk of death.
Original language | English (US) |
---|---|
Pages (from-to) | 1078-1087 |
Number of pages | 10 |
Journal | Clinical calcium |
Volume | 20 |
Issue number | 7 |
State | Published - Jul 2010 |
ASJC Scopus subject areas
- Medicine(all)